- Trials with a EudraCT protocol (6)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
6 result(s) found for: Enlarged Uterus.
Displaying page 1 of 1.
EudraCT Number: 2016-003727-27 | Sponsor Protocol Number: MVT-601-3001 | Start Date*: 2017-06-12 | ||||||||||||||||
Sponsor Name:Myovant Sciences GmbH c/o Vischer AG | ||||||||||||||||||
Full Title: LIBERTY 1: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Co Administered with and without Low-Dose Estradiol and Norethindron... | ||||||||||||||||||
Medical condition: heavy menstrual bleeding associated with uterine fibroids | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||
Trial protocol: GB (Completed) DE (Completed) PL (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-005113-50 | Sponsor Protocol Number: MVT-601-3002 | Start Date*: 2017-05-22 | ||||||||||||||||
Sponsor Name:Myovant Sciences GmbH | ||||||||||||||||||
Full Title: LIBERTY 2: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Co Administered with and without Low-Dose Estradiol and Norethindron... | ||||||||||||||||||
Medical condition: heavy menstrual bleeding associated with uterine fibroids | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||
Trial protocol: HU (Completed) CZ (Completed) BE (Completed) PL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-002783-40 | Sponsor Protocol Number: 000304 | Start Date*: 2019-07-04 | |||||||||||||||||||||||||||||||
Sponsor Name:Ferring Pharmaceuticals A/S | |||||||||||||||||||||||||||||||||
Full Title: A randomised, controlled, open label, parallel group, multicentre trial comparing the efficacy and safety of individualised FE 999049 (follitropin delta) dosing, using a long GnRH agonist protocol ... | |||||||||||||||||||||||||||||||||
Medical condition: Infertility in women undergoing assisted reproductive technologies (ART) such as an in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||||||||||||||||||||||
Trial protocol: AT (Completed) DK (Completed) NO (Completed) NL (Completed) IT (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-023957-12 | Sponsor Protocol Number: RAPIDO | Start Date*: 2011-03-29 | |||||||||||
Sponsor Name:Dutch Colorectal Cancer Group [...] | |||||||||||||
Full Title: Randomized Multicentre Phase III study of short course radiation therapy followed by prolonged pre-operative chemotherapy and surgery in primary high risk rectal cancer compared to standard chemor... | |||||||||||||
Medical condition: primary rectal cancer without detectable distant metastasis, but with a high risk to relapse locally or systemically. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Ongoing) NL (Ongoing) ES (Ongoing) SI (Ongoing) DK (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000753-80 | Sponsor Protocol Number: 000298 | Start Date*: 2022-08-04 | |||||||||||
Sponsor Name:Ferring Pharmaceuticals A/S | |||||||||||||
Full Title: A randomised, assessor-blind, active-controlled, parallel-group, dose-finding trial to investigate the efficacy and safety of FE 999302 for triggering of final follicular maturation in women underg... | |||||||||||||
Medical condition: Infertility | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) CZ (Prematurely Ended) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001320-19 | Sponsor Protocol Number: CTX001-121 | Start Date*: 2018-12-05 | |||||||||||
Sponsor Name:Vertex Pharmaceuticals Incorporated | |||||||||||||
Full Title: A Phase 1/2/3 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001) in Subjects With Severe Sick... | |||||||||||||
Medical condition: Severe Sickle Cell Disease (SCD) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Ongoing) GB (GB - no longer in EU/EEA) DE (Completed) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.